Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Islet Studies

Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro

A Balance Between Proliferation and Differentiation

  1. Corentin Cras-Méneur,
  2. Lynda Elghazi,
  3. Paul Czernichow and
  4. Raphael Scharfmann
  1. INSERM U457, Hospital R. Debré, Paris, France
    Diabetes 2001 Jul; 50(7): 1571-1579. https://doi.org/10.2337/diabetes.50.7.1571
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Figures

    • FIG. 1.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 1.

      Effect of the inhibitor of the MAP kinase pathway PD98059 on cell proliferation and differentiation. Pancreatic epithelia were grown in culture for 3 days in the absence or presence of PD98059 (50 μmol/l). A: Immunostaining for BrdU (red) and insulin plus glucagon (green) in controls (DMSO) and PD98059-treated rudiments. B: Quantification of the size and number of BrdU-positive cells and the cell surface area occupied by insulin/glucagon−positive cells that developed during 3 days in the presence of PD98059 when compared with control rudiments grown for the same period in the absence of PD98059. The sizes of the epithelia and total surface of insulin/glucagon−positive cells were also determined before culture. Three rudiments were analyzed for each condition. Data are means ± SE. *P < 0.05.

    • FIG. 2.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 2.

      Effect of EGF on the size of pancreatic epithelia in culture. e13.5 pancreatic epithelial rudiments grown in culture for 7 days with or without EGF. A: Photographs of the epithelia before and after 7 days of culture. The pictures were taken at the same magnification. Left panel: an epithelium before culture; middle panel: an epithelium grown for 7 days in control conditions, with endocrine budding visible (arrows); right panel: an epithelium grown for 7 days with EGF. B: Quantification of the total size of the epithelial rudiments before and after 7 days in culture in the absence or in the presence of EGF. The surface of all sections prepared for immunohistochemistry were measured and areas of all sections were added. Seven rudiments were analyzed for each condition. Mean values in μm2 ± SE are shown on the graph. **P < 0.005.

    • FIG. 3.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 3.

      Immunohistological analysis of pancreatic epithelium grown in vitro during 7 days with or without EGF. Pancreatic epithelia were grown for 7 days without or with EGF. They were sectioned and consecutive sections were stained for amylase or insulin and glucagon. A: Superimposition of staining from adjacent sections for amylase (green), insulin (red), and glucagon (blue, artificial color) in epithelia developed without (control) or with EGF. B: Absolute surface areas in μm2 occupied by insulin- (left) and glucagon-expressing (right) cells in rudiments grown for 7 days with or without EGF. Six to seven rudiments were analyzed for each condition. **P < 0.005.

    • FIG. 4.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 4.

      Characterization of the cells developed in the presence of EGF that stain negative for endocrine and acinar markers. A and B: Pancreatic epithelia were grown for 7 days in the absence (A) or presence of EGF (B). Consecutive sections were analyzed by immunohistochemistry for amylase (green), cytokeratin (red), insulin plus glucagon (blue, artificial color), and vimentin (yellow, artificial color). The images were next superimposed. Note that in EGF-treated rudiments, nearly all cells that stained negative for endocrine and acinar markers expressed high levels of cytokeratin. Moreover, very few cells stained positive for vimentin, either in the presence or absence of EGF. C−E: Pancreatic epithelia were grown for 7 days without (C) or with (D and E) EGF. Double-staining for cytokeratin (red) and BrdU (green). The picture presented in (E) was obtained after confocal microscopy.

    • FIG. 5.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 5.

      Epithelial cells that developed during the first week of culture in the presence of EGF differentiated into insulin-expressing cells when EGF was removed. A: Pancreatic epithelia were grown for 7 days with (a and b) or without EGF (c and d). The rudiments were either fixed (a and c) or grown for an additional week in the absence of EGF (b and d). The rudiments were sectioned and analyzed by immunohistochemistry for insulin. B: Quantification of insulin-positive cell mass that developed in each condition. An 8.93-fold (P < 0.005) increase in the insulin-positive cell mass occurred during the second week of culture when EGF was removed at day 7. Moreover, at day 14, more insulin-expressing cells developed (P < 0.05) when the rudiments were grown during the first week with EGF and during the second week in the absence of EGF when compared with rudiments grown 2 weeks in the absence of EGF. Six to seven rudiments were analyzed in each condition. *P < 0.05; **P < 0.005; NS, not significantly different.

    • FIG. 6.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 6.

      Insulin-expressing cells that developed after EGF removal derived from cells that proliferated when EGF was present. Pancreatic epithelia were grown for 7 days with EGF and pulsed with BrdU (10 μmol/l) during the last 6 h. They were either fixed (A) or kept in culture without BrdU during an additional week in the absence of EGF (B) and finally fixed. They were sectioned and immunohistochemistry for insulin (green) and BrdU (red) was performed. Although insulin-expressing cells present at day 7 stained negative for BrdU, some insulin-expressing cells found at day 14 stained positive for BrdU (white arrows), indicating that such insulin-expressing cells differentiated during the second week of culture in the absence of EGF from cells that were proliferating when EGF was present.

    PreviousNext
    Back to top

    In this Issue

    July 2001, 50(7)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro
    Corentin Cras-Méneur, Lynda Elghazi, Paul Czernichow, Raphael Scharfmann
    Diabetes Jul 2001, 50 (7) 1571-1579; DOI: 10.2337/diabetes.50.7.1571

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro
    Corentin Cras-Méneur, Lynda Elghazi, Paul Czernichow, Raphael Scharfmann
    Diabetes Jul 2001, 50 (7) 1571-1579; DOI: 10.2337/diabetes.50.7.1571
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
    • Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with KATP Channels
    • Pancreatic β-Cell–Specific Deletion of VPS41 Causes Diabetes Due to Defects in Insulin Secretion
    Show more Islet Studies

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.